ReviewClinical cardiology2017
Comprehensive primary prevention of cardiovascular disease in women.
Review in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? - assessing its cost-effectiveness.The international journal of behavioral nutrition and physical activity · 2022Pooled it
- Pooled it
- Postpartum Interventions to Reduce Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: A Systematic Review.Frontiers in cardiovascular medicine · 2019Pooled it
- Resting blood pressure reductions following handgrip exercise training and the impact of age and sex: a systematic review and narrative synthesis.Systematic reviews · 2018Pooled it
- More Data Needed.Deutsches Arzteblatt international · 2025Article
- Explanation of chronic stressors in older women with uterine fibroids-a qualitative study.Frontiers in public health · 2025Article
- Clinical Evaluation of Patients with Genetically Confirmed Familial Hypercholesterolemia.Journal of clinical medicine · 2023Article
- Sex and gender aspects in diabetes mellitus: Focus on access to health care and cardiovascular outcomes.Frontiers in public health · 2023Article
- Clustering of behavioral risk factors for chronic noncommunicable diseases in climacteric women.Einstein (Sao Paulo, Brazil) · 2022Article
- Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.Atherosclerosis · 2020Article
- Cardiovascular Diseases in Women: Policies and Practices Around the Globe to Achieve Gender Equity in Cardiac Health.Risk management and healthcare policy · 2020Review
- Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study.Advances in therapy · 2019Article
- Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosis.Cardiovascular research · 2019Article
- Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction.Circulation · 2019Article
- Comprehensive primary prevention of cardiovascular disease in women.Clinical cardiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality in women. Historically, medical research has focused on male patients, and subsequently, there has been decreased awareness of the burden of ASCVD in females until recent years. The biological differences between sexes and differences in societal expectations defined by gender roles contribute to gender differences in ASCVD risk factors. With these differing risk profiles, risk assessment, risk stratification, and primary preventive measures of ASCVD are different in women and men. In this review article, clinicians will understand the risk factors unique to women, such as preeclampsia, gestational diabetes, and those that disproportionately affect them such as autoimmune disorders. With these conditions in mind, the approach to ASCVD risk assessment and stratification in women will be discussed. Furthermore, the literature behind the effects of primary preventive measures in women, including lifestyle modifications, aspirin, statins, and anticoagulation, will be reviewed. The aim of this review article was to ultimately improve ASCVD primary prevention by reducing gender disparities through education of physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.